Research Articles - Macular Degeneration
The IMT provides improved central and detailed vision by focusing and magnifying images onto the functional, outer regions of the recipient’s retina. People with advanced AMD normally experience degeneration of the macula or central region of the retina.
In clinical studies, the device has helped people improve their ability to read, recognize faces, and perform other detailed-oriented tasks. In a 219-participant study, 75 percent of recipients had their level of vision improved from severe impairment to moderate impairment.
Owings Mills, MD — An innovative technology, employing a tiny capsule implanted in the eye, is stabilizing vision in people suffering from dry age-related macular degeneration (AMD). Encapsulated Cell Technology (ECT), developed by Rhode Island-based Neurotech, preserved vision in a majority of the 51 people who participated in a Phase II clinical trial.
There are currently no treatments for dry AMD, which is a leading cause of blindness for people 55 and older in developed countries.
- An emerging low-radiation treatment for wet age-related macular degeneration (AMD) known as Oraya Therapy™ reduced the number of Lucentis™ injections that people receive for the treatment of recurring wet AMD. In Oraya’s 230-person, Phase II/III clinical trial across Europe, the treatment reduced the need for Lucentis injections by 32 percent.
- A 21,000-participant study suggests that moderate alcohol consumption — more than one drink per day — increases the risk of early age-related macular degeneration (AMD) by 20 percent and advanced AMD by 44 percent. The report in the American Journal of Epidemiology was authored by investigators from the Centre for Eye Research Australia.
The research team says that, until its study, there was little evidence
Researchers have determined that a common blood test for assessing cardiovascular disease risk can also indicate risk for age-related macular degeneration (AMD). They found that people with high levels of high-sensitivity C-reactive protein (hsCRP) — a biomarker for inflammation related to heart disease, cancer and other conditions — have a 49 percent greater risk of all forms of AMD compared to those with low levels of hsCRP. High levels of hsCRP are also associated with an 84 percent increased
- The biopharmaceutical company Regeneron has received FDA approval for Eylea™, its treatment for wet age-related macular degeneration (AMD) that is as effective as currently prescribed wet AMD therapies such as Lucentis® but requires less-frequent ocular injections.
“Fewer injections with Eylea should translate to reduced risk of injection-related discomfort and complications for patients while not
- The National Eye Institute (NEI) reports that second-year results from its Comparison of AMD Treatments Trial (CATT) show that Lucentis and Avastin are similarly safe and effective in halting and reversing vision loss for people with wet age-related macular degeneration (AMD). The second-year CATT results, published on April 30, 2012, in the journal Ophthalmology, are consistent with
An innovative, targeted search technique known as whole-exome sequencing is dramatically reducing the time, effort and expense it takes to discover genetic defects that cause retinal disease. While the increasing raw power of genetic-screening technologies is continually accelerating the pace of gene discoveries, the whole-exome search strategy is a major leap forward.
Drs. Albert Maguire, Katherine High and Jean Bennett of CHOP have successfully reversed blindness in twelve LCA patients.
CHOP researchers began the study two years ago and, in 2008, reported vision improvement for their first three participants, all of whom were young adults. The results of these first participants were heralded worldwide as one
Researchers around the world are calling it a scientific breakthrough; a medical milestone. Corey’s parents, Ethan and Nancy, call it a dream come true.
Ethan, Nancy and Corey Haas
attend a press conference at
The Children’s Hospital of Philadelphia
Just 13 months ago Corey was almost completely blind. With poor visual acuity, little color perception and a very limited visual field, he was challenged in